You just read:

Medicenna Presents Promising Update from its MDNA55 Clinical Trial in Recurrent Glioblastoma at the Targeting Innate Immunity Congress

News provided by

Medicenna Therapeutics Corp.

Sep 25, 2019, 08:22 ET